BSH 2023 | ENABLE: third-generation anti-CD19 CAR for R/R NHL
Robert Weinkove, MA (Cantab), MBBS (Hons), PhD, FRACP, FRCP, Malaghan Institute of Medical Research, Wellington, New Zealand, gives an update on the ongoing ENABLE trial (NCT04049513). The Phase I escalation study aims to identify a safe dose of third-generation anti-CD19 CAR T-Cells (WZTL-002) in the treatment of patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Dr Weinkove highlights the lack of neurotoxicity observed amongst the treated cohort. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Institutional research funding from BioOra, Wellington Zhaotai Therapies Limited and Janssen. Advisory Board and speaker fees from Janssen and AbbVie.
